368 related articles for article (PubMed ID: 33768297)
21. Galactorrhea - side effect of risperidone in combination with depakine chrono in a patient with bipolar disorder.
Peitl MV; Peitl V; Grahovac T; Pavlović E
Psychiatr Danub; 2010 Mar; 22(1):125-7. PubMed ID: 20305608
[TBL] [Abstract][Full Text] [Related]
22. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI.
Grohmann R; Rüther E; Engel RR; Hippius H
Pharmacopsychiatry; 1999 Jan; 32(1):21-8. PubMed ID: 10071179
[TBL] [Abstract][Full Text] [Related]
23. Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program.
Konstantinidis A; Papageorgiou K; Grohmann R; Horvath A; Engel R; Kasper S
Int J Neuropsychopharmacol; 2012 May; 15(4):449-57. PubMed ID: 21733242
[TBL] [Abstract][Full Text] [Related]
24. Edema related to treatment with psychotropic drugs.
Engel J; Haack B; Zolk O; Greiner T; Heinze M; Toto S; Seifert J; Bleich S; Glocker C; Grohmann R; Schneider M; Stübner S
J Neural Transm (Vienna); 2024 Mar; 131(3):253-266. PubMed ID: 38353811
[TBL] [Abstract][Full Text] [Related]
25. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.
Kim KS; Pae CU; Chae JH; Bahk WM; Jun TY; Kim DJ; Dickson RA
J Clin Psychiatry; 2002 May; 63(5):408-13. PubMed ID: 12019665
[TBL] [Abstract][Full Text] [Related]
26. Impact of second-generation antipsychotics on the use of antiparkinson agents in nursing homes and assisted-living facilities.
Touré JT; Brandt NJ; Limcangco MR; Briesacher BA
Am J Geriatr Pharmacother; 2006 Mar; 4(1):25-35. PubMed ID: 16730618
[TBL] [Abstract][Full Text] [Related]
27. [Endocrine side effects among psychiatric patients treated with antipsychotics].
Kovács L; Kovács G
Neuropsychopharmacol Hung; 2006 Jun; 8(2):61-6. PubMed ID: 17073213
[TBL] [Abstract][Full Text] [Related]
28. Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015.
Schneider M; Regente J; Greiner T; Lensky S; Bleich S; Toto S; Grohmann R; Stübner S; Heinze M
Eur Arch Psychiatry Clin Neurosci; 2020 Feb; 270(1):23-33. PubMed ID: 30506147
[TBL] [Abstract][Full Text] [Related]
29. The AMSP drug safety program: methods and global results.
Grohmann R; Engel RR; Rüther E; Hippius H
Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S4-11. PubMed ID: 15052509
[TBL] [Abstract][Full Text] [Related]
30. Sex differences in pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001 to 2017.
Seifert J; Führmann F; Reinhard MA; Engel RR; Bernegger X; Bleich S; Stübner S; Rüther E; Toto S; Grohmann R; Sieberer M; Greil W
J Neural Transm (Vienna); 2021 Jun; 128(6):827-843. PubMed ID: 33977402
[TBL] [Abstract][Full Text] [Related]
31. Reversible Amisulpride-induced Elevation of Creatine Kinase (CK): A Case Series from the German AMSP Pharmacovigilance Project.
Laoutidis ZG; Konstantinidis A; Grohmann R; Luckhaus C; Mobascher J; Cordes J
Pharmacopsychiatry; 2015 Jul; 48(4-5):178-81. PubMed ID: 25984709
[TBL] [Abstract][Full Text] [Related]
32. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
33. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology.
Windgassen K; Wesselmann U; Schulze Mönking H
Neuropsychobiology; 1996; 33(3):142-6. PubMed ID: 8776743
[TBL] [Abstract][Full Text] [Related]
34. Safety Profile of Antipsychotic Drugs: Analysis Based on a Provincial Spontaneous Reporting Systems Database.
Guo K; Feng Z; Chen S; Yan Z; Jiao Z; Feng D
Front Pharmacol; 2022; 13():848472. PubMed ID: 35355731
[No Abstract] [Full Text] [Related]
35. Pharmacotherapy of 1,044 inpatients with posttraumatic stress disorder: current status and trends in German-speaking countries.
Reinhard MA; Seifert J; Greiner T; Toto S; Bleich S; Grohmann R
Eur Arch Psychiatry Clin Neurosci; 2021 Sep; 271(6):1065-1076. PubMed ID: 33369692
[TBL] [Abstract][Full Text] [Related]
36. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.
Kinon BJ; Ahl J; Liu-Seifert H; Maguire GA
Psychoneuroendocrinology; 2006 Jun; 31(5):577-88. PubMed ID: 16488084
[TBL] [Abstract][Full Text] [Related]
37. Risperidone-induced galactorrhea associated with a prolactin elevation.
Popli A; Gupta S; Rangwani SR
Ann Clin Psychiatry; 1998 Mar; 10(1):31-3. PubMed ID: 9622047
[TBL] [Abstract][Full Text] [Related]
38. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
Lambert M; Haro JM; Novick D; Edgell ET; Kennedy L; Ratcliffe M; Naber D
Acta Psychiatr Scand; 2005 Mar; 111(3):232-43. PubMed ID: 15701108
[TBL] [Abstract][Full Text] [Related]
39. Menstrual disturbance and galactorrhea in people taking conventional antipsychotic medications.
Thangavelu K; Geetanjali S
Exp Clin Psychopharmacol; 2006 Nov; 14(4):459-60. PubMed ID: 17115873
[TBL] [Abstract][Full Text] [Related]
40. Generalization to atypical antipsychotic drugs depends on training dose in rats trained to discriminate 1.25 mg/kg clozapine versus 5.0 mg/kg clozapine versus vehicle in a three-choice drug discrimination task.
Prus AJ; Philibin SD; Pehrson AL; Porter JH
Behav Pharmacol; 2005 Nov; 16(7):511-20. PubMed ID: 16170228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
